Trial Profile
Inhibition of Disease Progression in Hepatitis C-Infected Patients With Compensated Liver Cirrhosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough
- 09 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 27 Dec 2008 New trial record.